SFA Therapeutics is a biopharmaceutical company specializing in the treatment of chronic inflammatory disease. The company develops a platform that is based on immuno-modulation of inflammatory factors derived from the human gut microbiome. Its pipeline includes treatments for psoriasis, liver cancer (hepatitis B, NASH, and HCC), ophthalmic diseases, cytokine release syndrome, and other diseases.